6 articles on this topic
David Foster
April 21, 2026
Stage 3 pleural mesothelioma survival data broken down by cell type, treatment, and prognostic factors. Median OS 15-19 months with surgery; 14% 5-year survival with immunotherapy. 5 treatment paths explained for 2026.
David Foster
March 8, 2026
Johns Hopkins Kimmel Cancer Center's perioperative immunotherapy trials show 80% surgical completion and extended survival for mesothelioma patients. Learn who qualifies.
David Foster
February 19, 2026
NCI awards $10.7M to Penn for CAR T-cell therapy targeting mesothelin in mesothelioma. Explore clinical data, eligibility, and breakthrough cell immunotherapy.
David Foster
February 11, 2026
Mayo Clinic's #1-ranked mesothelioma program delivers multidisciplinary treatment with access to clinical trials across Rochester, Phoenix, and Jacksonville locations.
David Foster
January 31, 2026
FDA-approved Opdivo + Yervoy now has 5-year data: 14% long-term survival vs 6% with chemo. Learn who qualifies for mesothelioma immunotherapy in 2026.
David Foster
January 28, 2026
Explore the best mesothelioma treatment options in 2026, including 56+ active clinical trials, immunotherapy advances, and targeted therapies like pegargiminase that are improving survival rates.
Our experienced mesothelioma attorneys are here to help you understand your options.